# A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis

> **NCT07237568** · PHASE3 · RECRUITING · sponsor: **Lynk Pharmaceuticals Co., Ltd** · enrollment: 352 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** LNK01001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07237568
- **Lead sponsor:** Lynk Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-29
- **Primary completion:** 2026-11
- **Final completion:** 2027-09
- **Target enrollment:** 352 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07237568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07237568, "A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07237568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*